A carregar...
CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer
Cell-cycle abnormalities are common in estrogen receptor- and/or progesterone receptor-positive, and HER2-non-overexpressing (HR+/HER2-) breast cancer, and have long been considered potential therapeutic targets. Cyclin-dependent kinase (CDK) 4/6 inhibitors have dramatically changed the therapeutic...
Na minha lista:
| Publicado no: | Breast |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elsevier
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7758367/ https://ncbi.nlm.nih.gov/pubmed/33352521 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.breast.2020.12.006 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|